{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:00:40Z","timestamp":1772805640348,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Trials have not assessed the effect of dalfampridine-extended release (dalfampridine-ER) on health utility. We sought to evaluate the effect of dalfampridine-ER tablets (prolonged-release fampridine in Europe) on health utility in patients with multiple sclerosis (MS) by mapping subjects\u2019 individual item scores from the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) onto the Euroqol 5-Dimension (EQ-5D) health utility index.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data from study MS-F203, a randomized trial of dalfampridine-ER tablets, 10\u00a0mg twice daily, in patients with MS, were used to calculate the health utility scores with two MSWS-12 to EQ-5D mapping equations (one derived in a North American [NA] registry, the other a United Kingdom [UK] registry). MS-F203 participants were categorized as dalfampridine-ER 20%-responders (achieving \u226520% improvement on the Timed 25-Foot Walk), dalfampridine-ER 20%-nonresponders (&lt;20% improvement), or placebo patients. Mean change in health utility scores from baseline to each double-blind treatment evaluation (visits 3-6 occurring at post-randomization weeks 2, 6, 10, and 14) and each off-drug follow-up evaluation (visits 7-8 occurring at weeks 16 and 18) were calculated and reported as effect sizes (ESs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Using the NA-derived equation, dalfampridine-ER 20%-responders demonstrated improvement in health utility vs. placebo; starting at week 6 (mean difference in ES\u2009=\u20090.44, p\u2009=\u20090.002) and maintained at weeks 10 (ES\u2009=\u20090.41, p\u2009=\u20090.01) and 14 (ES\u2009=\u20090.71, p\u2009&lt;\u20090.001). These improvements were no longer evident after dalfampridine-ER was discontinued (p\u2009&gt;\u20090.05 at weeks 16 and 18). Dalfampridine-ER 20%-nonresponders did not show improvement vs. placebo at any visit (p\u2009&gt;\u20090.05 for all). When using the UK-derived equation, improvement was seen in dalfampridine-ER 20%-responders vs. placebo at weeks 2, 6, 10, and 14 (ESs\u2009=\u20090.49, 0.55, 0.59, and 0.99; p\u2009&lt;\u20090.03 for all), but not when dalfampridine-ER was discontinued (weeks 16 and 18; p\u2009&gt;\u20090.05 for both). Dalfampridine-ER 20%-nonresponders showed no improvement at any visit (p\u2009&gt;\u20090.05 for all).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Regardless of the equation used, dalfampridine-ER response was associated with an improvement in health utility.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7525-11-105","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T00:14:32Z","timestamp":1372205672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients"],"prefix":"10.1186","volume":"11","author":[{"given":"Brendan L","family":"Limone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew F","family":"Sidovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig I","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,26]]},"reference":[{"key":"1156_CR1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0025-7125(03)00008-7","volume":"87","author":"EM Frohman","year":"2003","unstructured":"Frohman EM: Multiple sclerosis. Med Clin North Am 2003, 87: 867\u2013897. 10.1016\/S0025-7125(03)00008-7","journal-title":"Med Clin North Am"},{"key":"1156_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","volume":"4","author":"NG Larocca","year":"2011","unstructured":"Larocca NG: Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 2011, 4: 189\u2013201. 10.2165\/11591150-000000000-00000","journal-title":"Patient"},{"key":"1156_CR3","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1212\/01.wnl.0000218309.01322.5c","volume":"66","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Atherly D, Hadjimichael O: Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006, 66: 1696\u20131702. 10.1212\/01.wnl.0000218309.01322.5c","journal-title":"Neurology"},{"key":"1156_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.60.1.31","volume":"60","author":"JC Hobart","year":"2003","unstructured":"Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ: Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003, 60: 31\u201336. 10.1212\/WNL.60.1.31","journal-title":"Neurology"},{"key":"1156_CR5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators: Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373: 732\u2013738. 10.1016\/S0140-6736(09)60442-6","journal-title":"Lancet"},{"key":"1156_CR6","volume-title":"The EuroQol instrument: An index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials. Second edition","author":"P Kind","year":"1996","unstructured":"Kind P: The EuroQol instrument: An index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials. Second edition. Philadelphia: Lippincott-Raven Publishers; 1996."},{"key":"1156_CR7","volume-title":"Value Health","author":"B Limone","year":"2012","unstructured":"Limone B, Sidovar M, Gaebler JA, Lee S, Coleman CI: Mapping the 12-Item Multiple Sclerosis Walking Scale to the EuroQol 5-Dimension Index Measure in American Multiple Sclerosis Patients. Value Health 2012. in press"},{"key":"1156_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/1352458511429319","volume":"18","author":"A Hawton","year":"2012","unstructured":"Hawton A, Green C, Telford C, Wright D, Zajicek J: The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Mult Scler 2012, 18: 853\u2013861. 10.1177\/1352458511429319","journal-title":"Mult Scler"},{"key":"1156_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1185\/03007995.2011.639752","volume":"28","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Sobieraj DM, Marinucci LN: Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin 2012, 28: 49\u201356. 10.1185\/03007995.2011.639752","journal-title":"Curr Med Res Opin"},{"key":"1156_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/135245850000600411","volume":"6","author":"M Kaufman","year":"2000","unstructured":"Kaufman M, Moyer D, Norton J: The significant change for the timed 25-foot walk in the Multiple Sclerosis Functional Composite. Mult Scler 2000, 6: 286\u2013290.","journal-title":"Mult Scler"},{"key":"1156_CR11","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1212\/WNL.58.8.1294","volume":"58","author":"SR Schwid","year":"2002","unstructured":"Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD: Quantitative functional measures in MS: what is a reliable change? Neurology 2002, 58: 1294\u20131296. 10.1212\/WNL.58.8.1294","journal-title":"Neurology"},{"key":"1156_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw JW, Johnson JA, Coons SJ: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005, 43: 203\u2013220. 10.1097\/00005650-200503000-00003","journal-title":"Med Care"},{"key":"1156_CR13","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ, USA: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"key":"1156_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4065\/77.4.371","volume":"77","author":"GH Guyatt","year":"2002","unstructured":"Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002, 77: 371\u2013383. 10.4065\/77.4.371","journal-title":"Mayo Clin Proc"},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2377-10-88","volume":"10","author":"J Zajicek","year":"2010","unstructured":"Zajicek J, Ingram W, Vickery J, Creanor S, Wright D, Hobart J: Patient-oriented longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort. BMC Neurol 2010, 10: 88. 10.1186\/1471-2377-10-88","journal-title":"BMC Neurol"},{"key":"1156_CR16","volume-title":"National Institute for Health and Clinical Excellence (NICE) Decision Support Unit (DSU) Technical Support Document 10: The use of mapping methods to estimate health state utility values","author":"L Longworth","year":"2011","unstructured":"Longworth L, Rowen D: National Institute for Health and Clinical Excellence (NICE) Decision Support Unit (DSU) Technical Support Document 10: The use of mapping methods to estimate health state utility values. 2011. http:\/\/www.nicedsu.org.uk"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7525-11-105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:38:01Z","timestamp":1630543081000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-11-105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,26]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1186\/1477-7525-11-105","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,26]]},"assertion":[{"value":"24 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"105"}}